2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-129724
    α-MSH (11-13) 67727-97-3 98%
    α-MSH (11-13) (ACTH-(11-13)) is a C-terminal tripeptide of α-MSH that can cross the blood-brain barrier. α-MSH (11-13) exhibits antipyretic, anti-inflammatory, and antibacterial activities. α-MSH (11-13) also exerts neuroprotective effects after traumatic brain injury by inhibiting excessive activation of microglia and reducing neuronal apoptosis. α-MSH (11-13) can be used in research related to traumatic brain injury, fever, and bacterial infections.
    α-MSH (11-13)
  • HY-129807
    LY-228729 115994-31-5 98%
    LY-228729 is a selective 5-HT1A receptor agonist. LY-228729 can reduce the rearing frequency of rats and decrease their activity in the central area in the open field test. LY-228729 can reduce the immobility time of rats and increase their swimming time in the forced swim test. LY-228729 can be used in the research of neurological diseases.
    LY-228729
  • HY-12980A
    Batefenterol Succinate 945905-37-3 98%
    Batefenterol Succinate (GSK961081 Succinate) is a first-of-its-kind inhaled bifunctional bronchodilator with smooth muscle relaxant properties. The activities of Batefenterol Succinate include acting as a smooth muscle parasympathetic antagonist and a beta2-adrenoceptor agonist. Batefenterol Succinate is used to improve respiratory function, especially in patients with chronic obstructive pulmonary disease (COPD).
    Batefenterol Succinate
  • HY-129810
    PD 135158 130325-35-8 98%
    PD 135158 (CAM 1028) is a selective CCKB receptor antagonist with an IC50 of 2.8 nM against mouse cortex CCKB. PD 135158 shows anxiolytic activity.
    PD 135158
  • HY-129822
    5-EAPB hydrochloride 1823776-22-2 98%
    5-EAPB hydrochloride is a benzofuran.
    5-EAPB hydrochloride
  • HY-129850
    4-Chloromethamphetamine hydrochloride 30572-91-9 98%
    4-Chloromethamphetamine hydrochloride is a new psychoactive substance belonging to the amphetamine class.
    4-Chloromethamphetamine hydrochloride
  • HY-129862
    Eclanamine maleate 67450-45-7 98%
    Eclanamine maleate is functionally categorized as a nontricyclic antidepressant.
    Eclanamine maleate
  • HY-129907
    2-AEMP 321882-95-5 98%
    2-AEMP (2-Aminoethyl methylphosphonate) is an anti-GABA(A)-ρ1 receptor compound with antagonist activity. 2-AEMP exhibits competitive inhibition compared to TPMPA with an IC(50) value of 18 μM, compared to 7 μM for TPMPA. The release rate of inhibition at termination of 2-AEMP is significantly higher than that of TPMPA. The preincubation time required for the onset of inhibition of 2-AEMP is much shorter than that of TPMPA. Some analogs of 2-AEMP, especially those with benzyl or n-butyl substituents, show lower potency in terms of biological activity.
    2-AEMP
  • HY-129931
    Phenylalanylphenylalanylamide 15893-46-6 98%
    Phenylalanylphenylalanylamide (H-Phe-Phe-NH₂) is a ligand for the substance P 1–7 (SP1-7) binding site with a Ki value of 1.5 nM. Phenylalanylphenylalanylamide exerts significant anti-allodynic and anti-hyperalgesic effects in animal models of neuropathic pain following central administratio. Phenylalanylphenylalanylamide shows no distinct effect after peripheral (intraperitoneal) administration. Phenylalanylphenylalanylamide can be used for research on pain-related diseases.
    Phenylalanylphenylalanylamide
  • HY-129947
    (-)-Carveol 1253216-40-8 98%
    (-)-Carveol is a natural unsaturated monocyclic monoterpene alcohol with the activity of regulating neural excitability. (-)-Carveol can activate or inhibit neural excitability by changing its chemical structure, which has potential significance for the design of targeted compounds. (-)-Carveol can also be used as a fragrance in cosmetics and a flavor additive in the food industry.
    (-)-Carveol
  • HY-129954
    6-EAPB hydrochloride 1823318-37-1 98%
    6-EAPB hydrochloride is a benzofuran.
    6-EAPB hydrochloride
  • HY-129985
    Clovoxamine 54739-19-4 98%
    Clovoxamine (DU23811) (Compound 35) has binding affinity for serotonin transporter (SERT) (Ki: 61 nM). Clovoxamine is a 5-HT and norepinephrine reuptake (NE) re-uptake inhibitor. Clovoxamine is an antidepressant.
    Clovoxamine
  • HY-130011
    CCG-232964 2349373-70-0 98%
    CCG-232964 is an orally active inhibitor of Rho/MRTF/SRF. CCG-232964 inhibits LPA-induced CTGF gene expression.
    CCG-232964
  • HY-130041
    Tropapride 76352-13-1 98%
    Tropapride is a dopamine D2 receptor antagonist. Tropapride can be used for the research of neurological disease.
    Tropapride
  • HY-130070
    QO-40 1259536-70-3 98.77%
    QO-40, a pyrazolo[1,5-a]pyrimidine-7(4H)-one (PPO) derivative, is a KCNQ2/KCNQ3 K+ channels activator with an EC50 of 6.94 μM. QO-40 stimulated Ca2+-activated K+ current (IK(Ca)) with an EC50 value of 2.3 μM in pituitary GH3 lactotrophs.
    QO-40
  • HY-130176
    UFP-512 480446-44-4 98%
    UFP-512 is a selective and potent σ-opioid receptor (DOP receptor) peptidic agonist with antidepressant- and anxiolytic-like effects. UFP-512 exhibits as a potent agonist on adenylyl cyclase inhibition and Erk1/2 activation. UFP-512 induces phosphorylation of DOP receptors on Ser363 with a low desensitization of the cAMP pathway. UFP-512 is promising for research of mood disorders.
    UFP-512
  • HY-130179
    RC-33 hydrochloride 1346016-43-0 98%
    RC-33 hydrochloride is a selective and metabolically stable σ receptor agonist with activity in enhancing nerve growth factor (NGF)-induced neurite outgrowth. Both enantiomers of RC-33 hydrochloride bind to the σ receptor with similar affinity and show almost equal effectiveness as σ receptor agonists. The R-configured enantiomer of RC-33 hydrochloride shows higher liver metabolic stability in the presence of NADPH. RC-33 hydrochloride was selected as the best candidate for further in vivo studies in animal models of amyotrophic lateral sclerosis.
    RC-33 hydrochloride
  • HY-130205
    Milacemide hydrochloride 76990-85-7 98%
    Milacemide hydrochloride (CP 1552 S), a glycinamide derivative, is an orally active MAO-B inhibitor with anticonvulsant activity. Milacemide hydrochloride reduces the levels of dihydroxyphenylacetic acid and homovanilic acid, but increases the levels of dopamine and serotonin in the caudate nucleus. Milacemide hydrochloride is promising for research of Alzheimer's disease.
    Milacemide hydrochloride
  • HY-130235
    Naprodoxime hydrochloride 58033-22-0 98%
    Naprodoxime hydrochloride is a derivative of Piracetam (HY-B0585). Naprodoxime hydrochloride acts as a potent antidepressant and anti-aggressive agent.
    Naprodoxime hydrochloride
  • HY-130351
    25H-NBOMe hydrochloride 1566571-52-5 98%
    25H-NBOMe hydrochloride is an agonist for the rat and human serotonin 5-HT2A receptors with Ki values of 1.19 and 2.83 nM, respectively.
    25H-NBOMe hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity